STA will Accelerate Process R&D and Manufacturing of Late Phase and Commercial Targets
STA Pharmaceutical Co., Ltd., (WuXi STA) – a subsidiary of WuXi AppTec – and Beta Pharma, a biotech company focusing on innovative drug discovery and development in oncology, announce a strategic partnership. Under the terms of the collaboration, WuXi STA will become the preferred CDMO partner of Beta Pharma, leveraging its platform to accelerate process R&D and manufacturing of later phase and commercial production – utilizing the Marketing Authorization Holder (MAH) scheme. Dr. Xiaodong Zhang, Founder and Chairman of Beta Pharma and Dr. Minzhang Chen, CEO of WuXi STA attended the strategic cooperation signing ceremony.
Beta Pharma is an emerging specialty pharmaceutical company dedicated to the discovery, development, and commercialization of innovative late stage therapies targeting oncology. The company has a pedigree spanning some 20 years of experiences in anticancer therapies and drugs and its founder Dr. Xiaodong Zhang and his team even participated in the molecular invention, development and listing in China of the first small molecule targeted anticancer drug, Icotinib. Today, Beta Pharma continues to expand its pipeline to integrate anticancer drugs and therapies, such as biopharmaceuticals, into its long-term development planning and strategies.
In February 2019, Beta Pharma officially launched the China registered Phase IIb, III clinical trial or the target BPI-7711 – a third generation of EGFR TKI that has a highly selective inhibitory effect on T790M mutations and EGFR single mutant tumors after a generation of EGFR TKI resistance. The company also has another target, BPI-1178, which has completed pre-clinical research and is expected to submit clinical application in early 2019.
WuXi STA was chosen as the strategic partner thanks to its industry leading “end-to-end” CMC platform for new drug development from preclinical to commercial – for both API and finished dosage forms – as well as its expertise and track record for meeting global quality standards.
“We’re delighted to partner with such a well-respected, world-class CDMO such as WuXi STA,” said Dr. Xiaodong Zhang, Founder and Chairman of Beta Pharma. “WuXi STA’s enabling end-to-end CMC platform and efficient, flexible solutions that meet the timeliness of our clinical and commercial use, will enable us to advance our pipeline more quickly worldwide.”
Dr. Minzhang Chen, CEO of WuXi STA, commented: “Our mission is to empower and accelerate customers to develop innovative drugs from clinical to commercial – faster and more efficiently. We are delighted to become the strategic partner of Beta Pharma and look forward to helping them advance their drug candidates towards the clinic, bringing innovative medicines for the benefit of patients around the world.”
About WuXi STA
STA Pharmaceutical Co., Ltd., a subsidiary of WuXi AppTec (WuXi STA), is a leading pharmaceutical development and manufacturing capability and technology platform company serving the life sciences industry, with operations in China and the United States. As a premier Contract Development and Manufacturing Organization (CDMO), WuXi STA offers our worldwide partners efficient, flexible and high-quality solutions for Active Pharmaceutical Ingredients (APIs) and finished dosage forms. For more information, please visit: https://sta.wuxiapptec.com/
